Mechanism

An investigational dual GLP-1 and glucagon receptor agonist. In research the combined activity is hypothesized to address appetite and glycemia (GLP-1) alongside increased energy expenditure (glucagon).

Research summary

Investigational and not FDA-approved. It has been studied for weight management and type 2 diabetes, with trials reported particularly in China. Larger-scale evaluation continues per the literature.

Reported side effects

Gastrointestinal effects are the most commonly reported in trials, consistent with the incretin class. Given glucagon activity, metabolic parameters are monitored. The full safety profile is not yet established.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Mazdutide (IBI362 / LY3305677) clinical trials · peer-reviewed clinical trials (2023)search PubMed for mazdutide; investigational
GLP-1/glucagon dual agonist reviews · peer-reviewed review articles (2023)investigational; not FDA-approved

TrackPep은 기록용 앱입니다. 사용자가 입력한 내용만 기록하며, 투여량을 추천하거나 계산하지 않습니다.